Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
-
Passage Bio to Participate in Upcoming April Investor Conferences
-
Passage Bio to Participate in Upcoming April Investor Conferences
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Modiv Acquisition Corp. (“MAC SPAC”) Announces Filing of Registration Statement
-
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
-
Renovacor to Come Public Through Merger with SPAC Chardan Healthcare Acquisition 2 Corp. (CHAQ)
-
Form 8-K Chardan Healthcare Acqui For: Mar 22
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
-
Chardan Expands Research Team, Welcomes Managing Director and Director of Research
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh
-
Solid Biosciences Announces Pricing of Public Offering of Common Stock
-
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
-
Solid Biosciences (SLDB) to Offer $85M in Common Stock
-
Solid Biosciences Announces Proposed Public Offering of Common Stock
-
Forte Biosciences Inc. (FBRX) PT Lowered to $105 at Chardan Capital Markets
-
4D Pharma Announces Private Placement
-
Solid Biosciences (SLDB) PT Raised to $20 at Chardan Capital Markets
-
ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets
-
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
-
Outcome Capital Expands Life Science Practice with Addition of Digital Health Industry Veterans
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Form S-1/A Chardan NexTech Acquisit
-
Form S-1 Chardan NexTech Acquisit
-
Passage Bio Inc. (PASG) PT Raised to $45 at Chardan Capital Markets
-
5 Penny Stocks To Watch This Week As Biotech Takes Spotlight
-
Form S-1 CHARDAN NEXTECH ACQUISIT
-
Quantum FinTech Acquisition Corporation Announces the Separate Trading of its Common Stock and Warrants, Commencing March 10, 2021
-
Quantum FinTech Acquisition Corporation Announces the Separate Trading of its Common Stock and Warrants, Commencing March 10, 2021
-
Chardan Capital Markets Upgrades Seres Therapeutics (MCRB) to Buy
-
Form 10-K Chardan Healthcare Acqui For: Dec 31
-
Taysha Gene Therapies (TSHA) PT Raised to $60 at Chardan Capital Markets
-
Senda Biosciences to virtually present at the Chardan 3rd Annual Microbiome Medicines Summit
-
4D Pharma to Present at Upcoming Investor Conferences in March
-
Vedanta Biosciences to Present at Upcoming Investor Conferences
-
Achilles Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Enterin to Present at Chardan's Virtual 3rd Annual Microbiome Medicines Summit
-
Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
-
Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
-
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
-
BiomX to Present at Upcoming March Investor Conferences
-
Emergent BioSolutions to Participate in Investor Conferences
-
Emergent BioSolutions to Participate in Investor Conferences
-
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
-
Chardan Capital Markets Upgrades Emergent BioSolutions (EBS) to Buy on Sell-Off
-
Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th
-
Lottery.com Enters into Definitive Agreement with Trident Acquisitions Corp. (TDAC) to Become Publicly Traded

